This is important for early detection of abnormalities in pregnancy, particularly in diabetic mothers.

We conclude that TAI is independently associated with is a higher risk of miscarriage in a population of unselected pregnant presenting a low risk of miscarriage.

Objectives: To evaluate abortion and fetal congenital anomaly rates in women previously submitted to radioiodine therapy for differentiated thyroid carcinoma. Study design: A case-control study of 108 pregnant women, 48 cases whose pregnancies were evaluated after they had undergone radioiodine therapy for differentiated thyroid carcinoma, and the control group consisted of 60 healthy pregnant women. Results: Of a total of 66 pregnancies, 14 conceived within the first year, 51 one or more years after the last administration of 131 I, the medical record of one patient was not available. The interval between the last radioiodine therapy administration and conception ranged from 1 month to 10 years. There were a total of 4 miscarriages, 2 of them for unknown reasons. There was one case of congenital anomaly and two preterms birth. Nine women presented the following pregnancy events: placental insufficiency, hypertensive crisis, placental detachment, risk of miscarriage, preterm labour and four miscarriages. No statistical difference was observed between the studied and control groups. Conclusion: Radioiodine was followed by no significant increase in untoward effects in neither the pregnancy nor the offspring. Objetivo: Avaliar a taxa de aborto e anomalia congênita em mulheres que engravidaram após radioiodoterapia para carcinoma diferenciado de tireóide. Pacientes e método: Estudo de caso controle com 108 mulheres, 48 submetidas à radioiodoterapia para carcinoma diferenciado de tireóide e 60 mulheres saudáveis (grupo controle). Resultados: De 66 gestações (grupo de pacientes que receberam radioiodo), 14 ocorreram no primeiro ano e 51 mais de um ano após a administração do 131 I. Não foi possível coletar dados de uma paciente. O intervalo entre a última dose de 131 I e a concepção variou de 1 mês a 10 anos. Ocorreram 4 abortos, 2 de causas desconhecidas. Houve 1 caso de anomalia congênita e 2 pretermos. Nove pacientes que receberam 131 I apresentaram intercorrências durante a gravidez: insuficiência placentária, crise hipertensiva, descolamento de placenta, ameaça de aborto, trabalho de parto prematuro e 4 abortos. Não houve diferença estatística entre o grupo estudado e o controle. Conclusão: O uso da radioiodoterapia para carcinoma diferenciado de tireóide em mulheres não foi relacionado com aumento de efeitos adversos nas mães e suas proles.

Our results suggest that TPOAb could be used as a screening test for PPTD prediction at least among women who present a high risk of developing PPTD.